CoChat

The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression

Open access

Published version of a preprint

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Purpose: Cancer immunotherapy has shown promising clinical outcomes in many patients. However, some patients still fail to respond, and new strategies are needed to overcome resistance. The purpose of this study was to identify novel genes and understand the mechanisms that confer resistance to cancer immunotherapy. Experimental Design: To identify genes mediating resistance to T-cell killing, we performed an open reading frame (ORF) screen of a kinome library to study whether overexpression of a gene in patient-derived melanoma cells could inhibit their susceptibility to killing by autologous tumor-infiltrating lymphocytes (TIL). Results: The RNA-binding protein MEX3B was identified as a top candidate that decreased the susceptibility of melanoma cells to killing by TILs. Further analyses of anti–PD-1–treated melanoma patient tumor samples suggested that higher MEX3B expression is associated with resistance to PD-1 blockade. In addition, significantly decreased levels of IFNγ were secreted from TILs incubated with MEX3B-overexpressing tumor cells. Interestingly, this phenotype was rescued upon overexpression of exogenous HLA-A2. Consistent with this, we observed decreased HLA-A expression in MEX3B-overexpressing tumor cells. Finally, luciferase reporter assays and RNA-binding protein immunoprecipitation assays suggest that this is due to MEX3B binding to the 3′ untranslated region (UTR) of HLA-A to destabilize the mRNA. Conclusions: MEX3B mediates resistance to cancer immunotherapy by binding to the 3′ UTR of HLA-A to destabilize the HLA-A mRNA and thus downregulate HLA-A expression on the surface of tumor cells, thereby making the tumor cells unable to be recognized and killed by T cells. Clin Cancer Res; 24(14); 3366–76. ©2018 AACR. See related commentary by Kalbasi and Ribas, p. 3239

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-2483

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 1

  1. Champion ChiP Transcription Factor Search Portal. 2012–05–12 ed. Valencia (CA): Qiagen; c2000.

Cited by

See all 104

Metadata

Authors
Huang, L., Malu, S., McKenzie, J. A., Andrews, M. C., Talukder, A. H., Tieu, T., Karpinets, T., Haymaker, C., Forget, M.-A., Williams, L. J., Wang, Z., Mbofung, R. M., Wang, Z.-Q., Davis, R. E., Lo, R. S., Wargo, J. A., Davies, M. A., Bernatchez, C., Heffernan, T., Amaria, R. N., Korkut, A., Peng, W., Roszik, J., Lizée, G., Woodman, S. E., & Hwu, P.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • 5Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • University of California, Los Angeles (US)
  • 1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Corresponding author
Hwu, Patrick
Venue
Clinical Cancer Research
Published
2018-07-15
Volume
24
Issue
14
Pages
3366-3376
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2792458296
Cited by
102
References
30
Citations by year
2026: 5 · 2025: 6 · 2024: 14 · 2023: 15 · 2022: 15 · 2021: 19 · 2020: 15 · 2019: 11 · 2018: 1
FWCI
4.32
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • HHS | National Institutes of Health (NIH) (R01CA184845, R01CA187076, P50CA093459, P30CA016672)
  • Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF)
  • Talla Family Revocable Trust
  • AIM at Melanoma (AIM at Melanoma Foundation)
  • Miriam and Jim Mulva Research Fund
  • Jurgen Sager and Transocean Melanoma Research Fund
  • El Paso Foundation for Melanoma Research
  • Cancer Prevention and Research Institute of Texas (CPRIT) (RP170401, RP140106, RP170067)
  • MDACC melanoma moonshots program
  • Melanoma Research Alliance (MRA)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
HLA-A, cancer immunotherapy resistance, anti-PD-1 therapy, melanoma, tumor-infiltrating lymphocytes, T cell-mediated killing, interferon-gamma, mRNA destabilization, 3' untranslated region, RNA-binding proteins, HLA downregulation
MeSH terms
Antineoplastic Agents, Immunological, Cytotoxicity, Immunologic, Humans, Interferon-gamma, Melanoma, Neoplasms, Protein Binding, Biomarkers, Tumor, HLA-A Antigens, Gene Expression Regulation, Neoplastic, Lymphocytes, Tumor-Infiltrating, RNA-Binding Proteins, Genes, Reporter, Drug Resistance, Neoplasm, 3' Untranslated Regions, Cell Line, Tumor, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-2483
The paper
Huang, L., Malu, S., McKenzie, J. A., Andrews, M. C., Talukder, A. H., Tieu, T., Karpinets, T., Haymaker, C., Forget, M.-A., Williams, L. J., Wang, Z., Mbofung, R. M., Wang, Z.-Q., Davis, R. E., Lo, R. S., Wargo, J. A., Davies, M. A., Bernatchez, C., Heffernan, T., . . . Hwu, P. (2018). The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-2483

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.